52162542-af1d-42ea-8f06-c6e042d9ac6c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74.7488021902806
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- HEDGEHOG_SIGNALING+0.420
- MYOGENESIS+0.350
- ANGIOGENESIS+0.320
- APICAL_JUNCTION+0.290
- APICAL_SURFACE+0.290
- WNT_BETA_CATENIN_SIGNALING+0.280
- COAGULATION+0.260
- UV_RESPONSE_DN+0.210
- IL6_JAK_STAT3_SIGNALING+0.160
Top 10 suppressed
- E2F_TARGETS-0.490
- MYC_TARGETS_V1-0.450
- G2M_CHECKPOINT-0.440
- OXIDATIVE_PHOSPHORYLATION-0.410
- PROTEIN_SECRETION-0.320
- ANDROGEN_RESPONSE-0.280
- FATTY_ACID_METABOLISM-0.240
- MITOTIC_SPINDLE-0.210
- MTORC1_SIGNALING-0.210
- CHOLESTEROL_HOMEOSTASIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-00083 | — | cohortMD2 | 0.899 |
| 2 | 20050037.TNBC | — | C | 0.892 |
| 3 | R116 | — | — | 0.886 |
| 4 | TCGA-XF-AAMJ-01A-11R-A42T-07 | — | — | 0.870 |
| 5 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.853 |
| 6 | SRR9879291 | — | cohortMD2 | 0.849 |
| 7 | 12305e97-f72f-4de7-9735-4cdbecb60296 | — | — | 0.846 |
| 8 | 40b98f15-43cb-426b-880c-951a4b28c3e2 | — | — | 0.846 |
| 9 | TCGA-BH-A8G0-01A-11R-A352-07 | — | A | 0.846 |
| 10 | SRR17866847 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |